Pages that link to "Q46309970"
Jump to navigation
Jump to search
The following pages link to Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group (Q46309970):
Displaying 50 items.
- Hormone therapy in postmenopausal women and risk of endometrial hyperplasia (Q24201543) (← links)
- Postmenopausal syndrome (Q26795412) (← links)
- Menopause and hormone-replacement therapy: Part 2. Hormone-replacement therapy regimens (Q28367961) (← links)
- Long-term hormone therapy for perimenopausal and postmenopausal women (Q30238978) (← links)
- Influence of body weight on the biochemical indicators in menopause (Q33669655) (← links)
- Hormone replacement therapy: where are we now? (Q33731351) (← links)
- Osteoporosis: prevention with estrogens in women over 60. (Q33786772) (← links)
- Recommendations for estrogen and progestin replacement in the climacteric and postmenopause. European Progestin Club (Q33828714) (← links)
- Moderation of the daily dose of HRT: benefits for patients (Q33830907) (← links)
- Moderation of the daily dose of HRT: prevention of osteoporosis (Q33830912) (← links)
- Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution (Q33909569) (← links)
- Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate (Q33949094) (← links)
- Update on the epidemiology of osteoporosis. (Q34108855) (← links)
- Estrogens and women's health: interrelation of coronary heart disease, breast cancer and osteoporosis (Q34132661) (← links)
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis (Q34158441) (← links)
- Role of estrogens in the management of postmenopausal bone loss (Q34206973) (← links)
- Role of estrogen on bone in the human male: insights from the natural models of congenital estrogen deficiency. (Q34280148) (← links)
- The 2002 Canadian bone densitometry recommendations: take-home messages. (Q34292278) (← links)
- Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects (Q34317537) (← links)
- Hormone replacement therapy: the benefits in tailoring the regimen and dose (Q34455239) (← links)
- Delayed oral estradiol combined with leuprolide increases endometriosis-related pain (Q34463853) (← links)
- HRT and cancer risks (Q34935090) (← links)
- Hormone replacement therapy: optimising the dose and route of administration (Q34995241) (← links)
- Estrogen, hormonal replacement therapy and cardiovascular disease (Q35070227) (← links)
- The rationale for low-dose hormonal therapy (Q38638662) (← links)
- In silico analysis of the molecular mechanism of postmenopausal osteoporosis (Q36224835) (← links)
- Canadian Consensus Conference on osteoporosis, 2006 update. (Q36454421) (← links)
- Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women (Q36570589) (← links)
- Care of the menopausal patient: a nurse practitioner's view (Q36892860) (← links)
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations (Q36959809) (← links)
- Dose-dependent cardiac effect of oestrogen replacement in mice post-myocardial infarction (Q37255529) (← links)
- Effect of isoflavone soy protein supplementation on endometrial thickness, hyperplasia, and endometrial cancer risk in postmenopausal women: a randomized controlled trial (Q37602011) (← links)
- Should symptomatic menopausal women be offered hormone therapy? (Q39337263) (← links)
- The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density (Q42165368) (← links)
- Oral, water-soluble combined estrogen/calcium preparation for postmenopausal therapy (Q43577864) (← links)
- Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism (Q43662494) (← links)
- The effects of oral estriol on the endometrium in postmenopausal women (Q44028324) (← links)
- A prospective, randomized, placebo-controlled study of the dose effect of oral estradiol on bone mineral density in postmenopausal Chinese women (Q44485602) (← links)
- Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results (Q44648884) (← links)
- In vivo metabolic tracking of 14C-radiolabelled isoflavones in kudzu (Pueraria lobata) and red clover (Trifolium pratense) extracts. (Q45935428) (← links)
- Hearing impairment and low bone mineral density increase the risk of bone fractures in women with Turner's syndrome (Q50461199) (← links)
- Effect of low-dose estrogen on hemodynamic response to stress (Q51970320) (← links)
- Estrogen therapy for osteoporosis in the modern era. (Q52665446) (← links)
- OESCLIM: summary of tolerability and safety (Q73416877) (← links)
- Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen (Q73543377) (← links)
- [Estrogens still and always?] (Q73940559) (← links)
- What factors account for hormone replacement therapy prescribing frequency? (Q74195850) (← links)
- Hormone replacement therapy (Q77088378) (← links)
- Association of a T262C transition in exon 1 of estrogen-receptor-alpha gene with skeletal responsiveness to estrogen in post-menopausal women (Q77415426) (← links)
- Prevention and treatment of osteoporosis in the elderly (Q77896123) (← links)